Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study

VIP study investigators, Zhigang Liu, James L. Alexander, Kaixing Le, Xin Zhou, Hajir Ibraheim, Sulak Anandabaskaran, Aamir Saifuddin, Kathy Weitung Lin, Leon R. McFarlane, Laura Constable, Rocio Castro Seoane, Nikhil Anand, Claire Bewshea, Rachel Nice, Andrea D'Mello, Gareth R. Jones, Sharmili Balarajah, Francesca Fiorentino, Shaji SebastianPeter M. Irving, Lucy C. Hicks, Horace RT Williams, Alexandra J. Kent, Rachel Linger, Miles Parkes, Klaartje Kok, Kamal V. Patel, Julian P. Teare, Daniel M. Altmann, Rosemary J. Boyton, Ailsa L. Hart, Charlie W. Lees, James R. Goodhand, Nicholas A. Kennedy, Katrina M. Pollock, Tariq Ahmad, Nick Powell*, Ijeoma Chukwurah, Sulaimaan Haq, Jonathan Lo, Parita Shah, Stephanie Wilken-Smith, Anitha Ramanathan, Mikin Patel, Lidia Romanczuk, Rebecca King, Jason Domingo, Djamila Shamtally, Vivien Mendoza, Anna Barnes

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study'. Together they form a unique fingerprint.

Immunology and Microbiology